<DOC>
	<DOC>NCT02520934</DOC>
	<brief_summary>evaluate the combination therapy with Miglustat and enzyme replacement therapy (ERT) on Gaucher disease</brief_summary>
	<brief_title>Miglustat on Gaucher Disease Type IIIB</brief_title>
	<detailed_description>understand if Miglustat (glucosylceramide synthase inhibitor) could improve neuropathy in patients with Gaucher disease</detailed_description>
	<mesh_term>Gaucher Disease</mesh_term>
	<mesh_term>Miglustat</mesh_term>
	<mesh_term>1-Deoxynojirimycin</mesh_term>
	<criteria>Case_Miglustat 1. Confirmed diagnosis of Gaucher Disease: blood test shown lack of beta glucocerebrosidase, and found L444P homozygous on GBA gene. 2. Aged 6 years old or above. 3. Already have regular ERT (30120 IU/kg/ every 2 weeks) at least a year; dosage and frequency of ERT had not been changed in recent 3 months. 1. History of tremor and abnormal extremities perception ( pain, numbness, tingle etc.) 2. Abnormal kidney function. 3. Pregnant or plan to have a baby ( potentially pregnant patient need to be transferred to gynecologist for the test and promise to have proper contraception measures). 4. Allergic to Miglustat. Control_normal Inclusion Criteria 1. Age 618 years 2. No significant physical, mental, or psychiatric problems Exclusion criteria 1. Children with eye disease (not include myopia, hyperopia, Astigmatism)</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Enzyme Replacement Therapy</keyword>
	<keyword>Miglustat</keyword>
	<keyword>Gaucher Disease</keyword>
</DOC>